P. MurugeshLet me be direct: EU AI Act vs FDA SaMD compliance is the most consequential dual-regulatory challenge facing digital health startups right now. Not eventually. Right now, in 2026, with the AI Act’s high-risk provisions fully operative. FDA’s Predetermined Change Control Plan (PCCP) guidance is simultaneously reshaping how machine-learning-enabled devices are reviewed on the US … Read more
The RPM Cybersecurity Shift: Navigating New FDA Mandates and Software Supply Chain Transparency in 2026 A Senior Cybersecurity Architect’s Field Guide — Because “We Think We’re Covered” Is No Longer Good Enough May 2026 | 20-minute read | Written for C-Suite, Regulatory Affairs, and QA Leadership Table of Contents 1. The Confidence Paradox: Why 90% … Read more
The RPM Cybersecurity Shift: Navigating New FDA Mandates and Software Supply Chain Transparency in 2026 A Senior Cybersecurity Architect’s Field Guide — Because “We Think We’re Covered” Is No Longer Good Enough May 2026 | 30-minute read | Written for C-Suite, Regulatory Affairs, and QA Leadership 📋 Table of Contents The Confidence Paradox: Why 90% … Read more
QMSR Transition: Harmonizing FDA 21 CFR 820 with ISO 13485:2016 — Post-Implementation Guide 2026 A post-implementation compliance and inspection readiness guide for medical device manufacturers — April 2026 Updated April 2026 | 18-minute read | FDA QMSR, ISO 13485:2016, CP 7382.850, ISO 14971 risk management Table of Contents The Day the QSR Died — and … Read more
The AI Drug Combination Discovery: 2026 Pharma Leader’s Guide provides an in-depth overview of the transformative impact of artificial intelligence on pharmaceutical development. With advancements in AI drug combination discovery, particularly through machine learning in pharma, the guide highlights the importance of computational drug combinations for optimising therapeutic efficacy. The incorporation of graph neural network drug synergy and digital twin pharma technologies facilitates enhanced drug synergy prediction AI, paving the way for innovative AI-driven combination therapy approaches. Furthermore, the exploration of quantum-classical hybrid drug discovery and multimodal AI pharma underscores the future of AI oncology drug combinations, positioning stakeholders to remain competitive in the evolving landscape.
AI Integration in Healthcare: Diagnostics, Imaging, Remote Monitoring & Surgical Tools — A Deep-Dive for Clinicians and Industry Professionals Updated March 2026 | 25-minute read | Peer-reviewed sources & real-world deployment data 📋 What You’ll Find in This Article The Integration Moment: Where Things Actually Stand in 2026 AI-Powered Diagnostics: Beyond the Buzzword Medical Imaging … Read more
AI Safety 2026: The New Pharma Standard – Regulated AI & Model Drift Monitoring AI Safety 2026: The New Pharma Standard – A comprehensive guide to regulated AI systems, model drift monitoring, and pharmaceutical compliance The pharmaceutical and medical device industries have officially moved past the “experimentation phase” of Artificial Intelligence. In boardrooms from Basel … Read more
The EU MedTech Innovation Pressure: Navigating 2026 “Crunch” and EY-DG SANTE Findings For years, the European Union was the global launchpad for EU MedTech Innovation, but recent data suggests a pivotal identity crisis is looming. A “CE Mark” was often the first major milestone for a startup before tackling the FDA. However, the tide has … Read more
The Future of Healthcare: How AI is Revolutionizing the US Pharmaceutical and Medical Device Industry (2026 Edition) The pharmaceutical and medical device landscape in the United States is undergoing its most significant transformation since the digital revolution. In 2025, Artificial Intelligence (AI) is no longer a “future concept”—it is the primary driver of efficiency, safety, … Read more
If you are a pharmacy student or a researcher in 2026, the old textbooks aren’t telling you the whole story. For decades, we learned that solubility was simple: “Like dissolves like.” We memorized the Noyes-Whitney equation, looked at a solubility chart, and mixed powders in a beaker. But today, that approach is obsolete. With 90% … Read more